Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2001
12/27/2001US20010055607 Intranosally administering of anesthetics
12/27/2001US20010055598 Mixture with solvent and hydrophobic carrier
12/27/2001US20010055594 Inhibiting Tumor Necrosis Factor (TNF)-alpha for treating nerve disorders by administering a TNF-alpha inhibitor selected from specified monoclonal antibodies; herniated discs, pain, nucleus pulposus-induced nerve injury, sciatica
12/27/2001US20010055571 Controlled unit dose to induce sedative-anxiolytic physiological response in the mammal, comprising lorazepam, nonaqueous, organic liquid solvent carrier and a preservative, in a manually actuated spray device
12/27/2001US20010055570 Cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDEs); using specified pyrazolopyrimidinone or aminoquinazoline derivatives
12/27/2001US20010055569 Nasal drug delivery composition
12/27/2001US20010055568 Oral, nasal and pulmonary dosage formulations of copolymer 1
12/27/2001US20010055565 Method of detecting cyclooxygenase-2
12/27/2001CA2414085A1 Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
12/27/2001CA2414064A1 Clear aqueous anaesthetic composition
12/27/2001CA2414046A1 Conserved diaphanous-related formin autoregulatory domain (dad)
12/27/2001CA2414020A1 Methods and compositions for the treatment of peripheral artery disease
12/27/2001CA2413878A1 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
12/27/2001CA2413554A1 Biotransformation of biologically active compounds made of various classes of chemical substances by means of laccase and manganese peroxidase enzymes
12/27/2001CA2413502A1 Tumour-cell specific gene expression and its use in cancer therapy
12/27/2001CA2413421A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
12/27/2001CA2413418A1 Piperidine amides as modulators of chemokine receptor activity
12/27/2001CA2413328A1 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
12/27/2001CA2413324A1 Treatment of central nervous system diseases by antibodies against glatiramer acetate
12/27/2001CA2413299A1 Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
12/27/2001CA2413284A1 Use of c4-c10 acids for preventing gram-negative bacterial infections
12/27/2001CA2413277A1 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl)
12/27/2001CA2413274A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
12/27/2001CA2412985A1 Hiv integrase inhibitors
12/27/2001CA2412905A1 Improved injectable dispersions of propofol
12/27/2001CA2412849A1 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
12/27/2001CA2412636A1 Method of treating cardiovascular disease using rapamycin
12/27/2001CA2412362A1 Cox-2 inhibitors and the prevention of the side effects of radiation therapy
12/27/2001CA2412215A1 Angiogenesis-modulating compositions and uses
12/27/2001CA2412199A1 Compositions containing 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivatives for the prevention and treatment of neurodegenerative diseases
12/27/2001CA2412188A1 3-azabicyclo¬3.1.0|hexane derivatives useful in therapy
12/27/2001CA2412141A1 Indole derivatives useful for the treatment of cns disorders
12/27/2001CA2412054A1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
12/27/2001CA2412011A1 Chemically-modified antimicrobial peptides, compositions and methods of production and use
12/27/2001CA2411865A1 Azaindole derivatives, process for their preparation, and their use as antitumor agents
12/27/2001CA2411756A1 Mutation associated with epilepsy
12/27/2001CA2411585A1 Novel non-psychotropic cannabinoids
12/27/2001CA2411553A1 New use of angiotensin ii antagonists
12/27/2001CA2411255A1 Novel compounds
12/27/2001CA2411236A1 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
12/27/2001CA2411100A1 New formulation comprising a betablocker and optionally a cholesterol-lowering agent
12/27/2001CA2410632A1 Nitrosated and nitrosylated taxanes, compositions and methods of use
12/27/2001CA2410452A1 1-aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
12/27/2001CA2410447A1 Bis-arylsulfones
12/27/2001CA2410358A1 A thiazine oxazolidinone
12/27/2001CA2410208A1 Systems and methods for treating a mucosal surface
12/27/2001CA2409776A1 G-protein coupled receptors
12/27/2001CA2407896A1 Medium chain fatty acids applicable as antimicrobial agents
12/27/2001CA2312505A1 Resveratrol compositions for topical use in the treatment of oral diseases and infections
12/26/2001CN1328573A Cross-linked hyaluronic acids and medical uses thereof
12/26/2001CN1328566A Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation
12/26/2001CN1328565A Antiviral purine derivatives
12/26/2001CN1328563A Organophosphorous compounds and use thereof
12/26/2001CN1328559A CRF receptor antagonists and methods relating thereto
12/26/2001CN1328558A Crystal modification A of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-chinolincarboxylique
12/26/2001CN1328557A Semi-hydrochloride of 8-cyan-1-cyclopropyl-7-(1S-2,8-diazabicyclo [4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid
12/26/2001CN1328556A Crystal modification B of 8-cyano-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0] nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid
12/26/2001CN1328554A Eletriptan hydrobromide monohydrate
12/26/2001CN1328553A 3-Tetrahydropyridin-4-yl indoles for treatment of psychotic disorders
12/26/2001CN1328552A Pyrimidone derivatives
12/26/2001CN1328550A Oxazole compounds as prostaglandin E2 agonists or antagonists
12/26/2001CN1328549A Substituted benzo [de] isoquinoline-1,3-diones
12/26/2001CN1328548A Benzamide derivatives as thrombin inhibitors
12/26/2001CN1328547A 2,3-Disubstituted pyridine derivatives, process for preparation thereof, drug compositions containing the same and intermediates for preparation
12/26/2001CN1328546A Pyrrolidines as inhibitors of neuraminidases
12/26/2001CN1328545A Hydrazine derivatives
12/26/2001CN1328538A 2,4-pentadienoic acid derivatives having selective activity for retinoid X(RXR) receptors
12/26/2001CN1328475A Coating useful as dispenser of active ingredient no dressings and bandages
12/26/2001CN1328473A Medicinal aerosol formulation
12/26/2001CN1328467A Buffered composition for dialysis
12/26/2001CN1328466A Use of antifungal agents for treating scleroses
12/26/2001CN1328465A Use of phosphonoformic acid derivatives for treating infections
12/26/2001CN1328464A Use of phosphonoformic acid derivatives for treating infections
12/26/2001CN1328463A Use of 17-ketosteroid compounds, as well as derivatives, metabolites and precursors for treatment of hapatitis C type virus and other togavirus infections
12/26/2001CN1328462A Use of staurosporine derivatives for treating ocular neovascular diseases
12/26/2001CN1328461A Method for preventing/treating damage to sensory hair cells and cochlear neurons
12/26/2001CN1328460A Pharmaceutical combination preparations
12/26/2001CN1328459A Oral dosage formulations comprising (2S, 3S, 5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol and effective stabilizing amount of alginic acid
12/26/2001CN1328458A Quinolinone derivative preparations and process for producing same
12/26/2001CN1328457A Use of N-substituted-1,5-dideoxy -1,5-imino-D-glucitol compounds for treating hepatitis virus
12/26/2001CN1328456A Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation
12/26/2001CN1328455A Use of N-substituted azabicycloalkane derivatives for treating diseases of central nervous system
12/26/2001CN1328454A Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
12/26/2001CN1328453A Pharmaceutical composition comprising combination of dextro-and laevo-isomers of sotalol
12/26/2001CN1328452A Use of benzoylguanidines for treatment of non-insulin-dependent diabetes mellitus
12/26/2001CN1328451A Drugs for improving vesical excretory strength
12/26/2001CN1328450A Particles coated with granulated crystalline ibuprofen
12/26/2001CN1328449A Application of water-soluble or water-dispersible polymerizates which contain poly-ether and which are used as coating agent, binding agent and/or as film-forming auxiliary agent in pharmaceutical for
12/26/2001CN1328448A Fentanyl composition for treatment of acute pain
12/26/2001CN1328447A Process for producing particles with converted amorphous and/or meta-stable crystalline region into crystalline state
12/26/2001CN1328446A Improved fast disintegrating tablet
12/26/2001CN1328445A Pressurised metered dose inhalers
12/26/2001CN1328417A Compositions and methods for treatment of mitochondrial diseases
12/26/2001CN1327833A Exterior-applied ointment for treating piles
12/26/2001CN1327832A Exterior-applied ointment for treating dermatitis
12/26/2001CN1327829A Tea leaf-seed ointment for treating scald and its preparing process
12/26/2001CN1327827A Exterior-applied medicine for treating dermatopathy
12/26/2001CN1327799A Mixture of white pepper and borneol and its application
12/26/2001CN1327795A Application of position-N desulfurizing heparin in preventing and treating inflammation
12/26/2001CN1327794A Vaginal minocycline suppository